Smith & Nephew PLC

Smith & Nephew is a global medical devices business operating in the markets for advanced surgical devices comprising orthopaedic reconstruction and trauma, sports medicine and advanced wound management. Co.'s advanced medical products and services include: Orthopaedic Reconstruction and Trauma (joint replacement systems for knees and hips and products to help repair broken bones); Advanced Wound Management (treatment and prevention products for hard-to-heal wounds); and Sports Medicine (implants and enabling technologies for minimally invasive repair of the joint).
  • TickerSN.
  • ISINGB0009223206
  • ExchangeLondon Stock Exchange
  • SectorHealth Care Equipment & Services
  • CountryUnited Kingdom

Smith & Nephew: 1 director maiden bought

A director at Smith & Nephew maiden bought 6,000 shares at 20.212USD and the significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names ...

SMITH & NEPHEW PLC. increases its risk exposure and slightly lowers to Neutral

SMITH & NEPHEW PLC. (GB), a company active in the Medical Equipment industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 2 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date May 1, 2020, the closing price was GBp 1,505.50 and its expected value was estimated at GBp 1,555.57.

Expert Corporate Governance Service (ECGS)

Smith & Nephew - AGM 09 April 2020

Item 3: Remuneration report Namal Nawana, CEO, stood down on 31 October 2019 after only 18 months in this job. According to the media, Mr. Nawana, who is based in Massachusetts, is leaving because his requests for higher pay, in line with the packages awarded by US medical device-makers, could not be met under UK corporate governance standards. We do not consider the CEO's departure conditions to be in line with the best UK practice. Although Mr. Nawana did not serve as CEO for the entire year, he received a full annual bonus, his LTI outstanding will not lapse and his total remuneration was ...

Jérôme VINERIER

Analyse court terme - SMITH & NEPHEW PLC : La tendance de fond est clairement orientée à la hausse.

La tendance de fond est clairement orientée à la hausse. Les cours progressent encore, mais le mouvement montre moins de puissance. La prochaine résistance est à 1 342,00 p. La rupture du support à 1 150,00 p invaliderait cette tendance.

Jérôme VINERIER

Short term view - SMITH & NEPHEW PLC : The background trend is clearly bullish.

The background trend is clearly bullish. Prices are still making progress but there is less power in the movement. The next resistance is at 1,342.00 p. Breaking below the support at 1,150.00 p would invalidate the trend.

Jérôme VINERIER

Analyse court terme - SMITH & NEPHEW PLC : La tendance est baissière.

La tendance est baissière. Les prix baissent à nouveau, mais le mouvement est devenu hésitant. Le prochain support est à 1 251,00 p. La tendance baissière serait remise en cause au-dessus de 1 408,83 p.

Jérôme VINERIER

Short term view - SMITH & NEPHEW PLC : The trend is bearish.

The trend is bearish. Prices are falling again, but the movement has become hesitant. The next support is at 1,251.00 p. The bearish trend would be challenged above 1,408.83 p.

Jérôme VINERIER

Analyse moyen terme - SMITH & NEPHEW PLC : Les cours baissent.

La tendance est incertaine. Les cours baissent, et il y a une possibilité d'accélération baissière. Une nouvelle tendance baissière tente de démarrer.

Smith & Nephew: 1 director maiden bought

A director at Smith & Nephew maiden bought 6,000 shares at 20.212USD and the significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names ...

MarketLine Department

B. Braun Melsungen AG - Strategy, SWOT and Corporate Finance Report

Summary B. Braun Melsungen AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights B. Braun Melsungen AG (B. Braun) is one of the leading suppliers of healthcare products in the fields of cardio-thoracic surgery, diabetes care, infection prevention, laparoscopic surgery, orthopaedic joint replacement, wound management, continence care & urology, extracorporeal blood ...

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior